The Patent Finder
JP

Jazz Pharmaceuticals, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

114 patents currently held

17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
38 more records may belong here and await a decision; they are not counted.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
17
Ending by 2030
Jan 2027
Next term end
53
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
Cited by 71 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
now held by Axsome Malta Ltd.
Ends Jun 2038 · High confidence
Also notable
Cited by 50 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2040.
now held by Axsome Malta Ltd.
Ends Mar 2040 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 19, 2026
    The maintenance fee for Novel Reference Plant, a Method for Its Production, Extracts Obtained Therefrom and Their Use (US 9,035,130) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
  • 2 fees due Dec 9 to 30, 2026 · next Dec 9
  • 1 fee due Feb 6, 2027
    The maintenance fee for Imipridones for Gliomas (US 10,369,154) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
  • 3 fees due Mar 5 to 15, 2027 · next Mar 5
  • 4 fees due Apr 17 to 30, 2027 · next Apr 17
  • 1 fee due May 28, 2027
    The maintenance fee for Pegylated L-Asparaginase (US RE49,736) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
  • 1 fee due Jun 17, 2027
    The maintenance fee for Remote Loading of Sparingly Water-Soluble Drugs into Liposomes (US 10,507,182) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Fused Bicyclic Raf Inhibitors and Methods for Use Thereof (US 11,858,930) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 2 fees due Aug 23 to 25, 2027 · next Aug 23
  • 1 fee due Sep 1, 2027
    The maintenance fee for Compositions for Delivery of Drug Combinations (US 9,271,931) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
  • 2 fees due Nov 7 to 14, 2027 · next Nov 7

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 17, 2026

What they patent

The 5 largest of its 53 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 7,850,990Compositions for Delivery of Drug Combinations
In force
 · Medium confidence
In forceMedium confidence
US 7,700,368Methods of Purifying Cannabinoids from Plant Material
In force
 · High confidence
In forceHigh confidence
US 8,481,085Pharmaceutical Compositions Comprising Cannabigerol
In force
 · High confidence
In forceHigh confidence
US 8,022,279Liposomal Formulations of Anthracycline Agents and Cytidine Analogs
In force
 · Medium confidence
In forceMedium confidence
US 9,168,278Use for Cannabinoid
In force
 · High confidence
In forceHigh confidence
US 9,795,567Immediate Release Formulations and Dosage Forms of Gamma-Hydroxybutyrate
In force
 · Medium confidence
In forceMedium confidence
US 9,017,737Use of Cannabinoids in Combination with an Anti-Psychotic Medicament
In force
 · High confidence
In forceHigh confidence
US 7,842,676Fixed Ratio Drug Combination Treatments for Solid Tumors
In force
 · High confidence
In forceHigh confidence
US 8,092,828Fixed Drug Ratios for Treatment of Hematopoietic Cancers and Proliferative Disorders
In force
 · High confidence
In forceHigh confidence
US 8,778,398Immediate Release Formulations and Dosage Forms of Gamma-Hydroxybutyrate
In force
 · Medium confidence
In forceMedium confidence
10 of 114 patents shown.
Pro members see all 114.
Pro members: see all 114 patents
Also on record, not counted in the 114: 17 patents in force now held by others · 29 patents ended · 46 applications pending · 47 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited